Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06963905 2026-02-17

SIMONE

Phase 1/2 Recruiting

60 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04595565 2025-11-25

SASCIA

Phase 3 Active not recruiting

1,332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07011654 2025-10-23

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

Phase 2 Recruiting

260 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

96 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03971409 2025-05-02

InCITe

Phase 2 Recruiting

150 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05770531 2025-04-04

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Phase 2 Recruiting

160 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

SIMONE

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

PRIMED

SASCIA

ADAPT-TN-III

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

NeoSTAR

ADAPT-TN-IV

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Trop-2 Targeted PET Probes in Advanced TNBC

ISIdE

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

InCITe

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy